Product Description
Mechanisms of Action: MTTP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Akros Pharma
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes|General Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2009-011965-10 |
PROMOTE | P2 |
Completed |
General Diabetes |
2010-05-06 |
2022-03-13 |
Treatments |
|
NCT00929539 |
AT130-G-08-006 | P2 |
Completed |
Type 2 Diabetes |
2010-05-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/01/2022 |
PubMed |
Reassessing the multiple values of lowland British floodplains. |
|
12/14/2021 |
PubMed |
Asylum seekers' and refugees' experiences of accessing health care: a qualitative study. |